SCHEMBL7408917

SCHEMBL7408917

[CH2]c1ccccc1C(C)C1CNCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 13/20 0.43
SLC6A4 P31645 13/20 0.43
SLC6A3 Q01959 8/20 0.43
MLNR O43193 1/20 0.43
ADRB2 P07550 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2C P28335 1/20 0.43
OPRK1 P41145 1/20 0.43
KCNH2 Q12809 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
SSTR4 P31391 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28236498 0.82 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL4631199 0.78 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL1961849 0.78 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL2463271 0.76 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL28227519 0.74 SSTR4 (0.46) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL28227466 0.73 SSTR4 (0.47) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL28825591 0.73 SSTR4 (0.45) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL28228207 0.72 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL8556232 0.72 SSTR4 (0.37) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL28048808 0.71 TLR8 (0.39) SLC6A2SLC6A4SLC6A3MLNRADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5426106-A Treatment of neurodegenerative diseases, schizophrenia, convulsions; selective non-competitive antagonists MERCK SHARP & DOHME LIMITED (GB) 1995-06-20 US claimed
US-5420155-A Treatment of nervous system disorders with derivatives of 4-hydroxy-2-(1H)-pyrrolones such as strokes, antiischemic agents or cardiovascular disorders MERCK SHARP & DOHME LTD. (GB) 1995-05-30 US claimed
US-5693640-A Pyridazino-indole derivatives MERCK, SHARP & DOHME, LTD. (GB) 1997-12-02 US disclosed
US-5614532-A NERVOUS SYSTEM DISORDERS USING N-METHYLASPARTATE ANTAGONIST MERCK, SHARP & DOHME LTD. (GB) 1997-03-25 US disclosed
EP-0481676-B1 Hydroxyquinolone derivatives MERCK SHARP & DOHME (GB) 1997-01-29 EP disclosed
US-5580877-A Pyrazolo-quinoline derivatives for treating cerebral ischemia MERCK SHARP & DOHME LTD. (GB) 1996-12-03 US disclosed
US-5559125-A NMDA AND AMPA RECEPTOR ANTAGONISTS, SCHIZOPHRENIA MERCK, SHARP & DOHME LIMITED (GB) 1996-09-24 US disclosed
US-5426106-A Treatment of neurodegenerative diseases, schizophrenia, convulsions; selective non-competitive antagonists MERCK SHARP & DOHME LIMITED (GB) 1995-06-20 US disclosed
US-5420155-A Treatment of nervous system disorders with derivatives of 4-hydroxy-2-(1H)-pyrrolones such as strokes, antiischemic agents or cardiovascular disorders MERCK SHARP & DOHME LTD. (GB) 1995-05-30 US disclosed
EP-0620812-A1 QUINOLONE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1994-10-26 EP disclosed
US-5348962-A Nervous system disorders; schizophrenia MERCK SHARPE & DOHME LTD. 1994-09-20 US disclosed
WO-1993011115-A2 QUINOLONE DERIVATIVES AND THEIR USE AS NMDA AND AMPA RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 1993-06-10 WO disclosed
EP-0481676-A1 Hydroxyquinolone derivatives MERCK SHARP & DOHME LTD. (GB) 1992-04-22 EP disclosed